Dmitriy Kolodin

Dmitriy Kolodin is a senior executive at AbbVie, a prominent biopharmaceutical company. Here's a comprehensive overview of his professional profile:

Current Position

Dmitriy Kolodin currently serves as the Vice President of Innovation at AbbVie.15 This role places him at the forefront of driving innovative initiatives within the company.

Professional Experience

Clinical Development Leadership: Prior to his current role, Kolodin held significant positions in clinical development at AbbVie:

• Vice President, Clinical Development Operations - Immunology, Neuroscience, and Capabilities4
• Operations Immunology, Neuroscience & Capabilities Vice President, Clinical Development3

In these roles, he was responsible for leading clinical development operations teams, focusing on delivering clinical trials and overseeing various aspects of drug development processes.2

Academic Background

Kolodin has a connection to prestigious academic institutions:

• Harvard University2
• Harvard Medical School (research affiliation)6

Research Contributions

Dmitriy Kolodin has made notable contributions to scientific research:

• He has authored 7 research works, which have garnered 2704 citations6
• His research has focused on areas such as regulatory T cells and their role in visceral adipose tissue6

Industry Recognition

Kolodin's expertise is recognized in the biopharmaceutical industry. He has been mentioned alongside other industry leaders in discussions about how biopharma commercial and R&D can partner effectively7, indicating his influence in the field.

Dmitriy Kolodin's diverse experience spanning clinical development, operations, and innovation in the biopharmaceutical sector, coupled with his research background, positions him as a key figure in driving advancements in drug development and healthcare innovation at AbbVie.